Silence Therapeutics plc (NASDAQ:SLN) Shares Sold by M28 Capital Management LP

M28 Capital Management LP decreased its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 38.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 185,100 shares of the company's stock after selling 114,300 shares during the quarter. Silence Therapeutics accounts for approximately 4.6% of M28 Capital Management LP's holdings, making the stock its 6th largest holding. M28 Capital Management LP owned 0.62% of Silence Therapeutics worth $3,517,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC grew its holdings in shares of Silence Therapeutics by 10.5% in the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company's stock valued at $151,000 after acquiring an additional 667 shares in the last quarter. Custom Index Systems LLC bought a new position in shares of Silence Therapeutics in the 2nd quarter valued at about $282,000. Legato Capital Management LLC bought a new position in shares of Silence Therapeutics in the 2nd quarter valued at about $376,000. Nicholas Investment Partners LP bought a new position in shares of Silence Therapeutics in the 2nd quarter valued at about $2,859,000. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company's stock valued at $4,046,000 after acquiring an additional 40,063 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.

Silence Therapeutics Stock Performance

Silence Therapeutics stock traded down $0.04 during midday trading on Friday, reaching $18.27. 275,427 shares of the company's stock were exchanged, compared to its average volume of 206,760. Silence Therapeutics plc has a 52 week low of $6.15 and a 52 week high of $27.72. The firm has a market cap of $546.78 million, a price-to-earnings ratio of -15.75 and a beta of 1.29. The stock's 50-day simple moving average is $18.57 and its 200 day simple moving average is $20.47.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.10). The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $11.28 million. Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. Research analysts forecast that Silence Therapeutics plc will post -1.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on SLN shares. Morgan Stanley raised their price objective on Silence Therapeutics from $45.00 to $49.00 and gave the company an "overweight" rating in a report on Friday, June 28th. Chardan Capital restated a "buy" rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Friday, August 16th. Jefferies Financial Group initiated coverage on Silence Therapeutics in a report on Tuesday, September 3rd. They set a "buy" rating and a $40.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Friday, August 30th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $57.20.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.